S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Minerva Neurosciences Stock Forecast, Price & News

-0.04 (-4.57%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
90,648 shs
Average Volume
143,760 shs
Market Capitalization
$35.67 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Minerva Neurosciences logo

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Waltham, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$41.18 million
Cash Flow
$0.05 per share
Book Value
$1.23 per share


Net Income
$1.94 million
Pretax Margin




Free Float
Market Cap
$35.67 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.21 out of 5 stars

Medical Sector

363rd out of 1,417 stocks

Pharmaceutical Preparations Industry

171st out of 683 stocks

Analyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

Is Minerva Neurosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences
or view top-rated stocks.

How has Minerva Neurosciences' stock price been impacted by Coronavirus?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NERV shares have decreased by 86.9% and is now trading at $0.8349.
View which stocks have been most impacted by COVID-19

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 376,300 shares, a decrease of 19.8% from the December 15th total of 469,300 shares. Based on an average daily trading volume, of 508,600 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.9% of the shares of the company are short sold.
View Minerva Neurosciences' Short Interest

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for Minerva Neurosciences

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.22) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.22). During the same period last year, the company posted ($0.19) earnings per share.
View Minerva Neurosciences' earnings history

What price target have analysts set for NERV?

2 equities research analysts have issued 12-month price targets for Minerva Neurosciences' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Minerva Neurosciences' stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 678.5% from the stock's current price.
View analysts' price targets for Minerva Neurosciences
or view top-rated stocks among Wall Street analysts.

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:
  • Rémy Henri Luthringer, Executive Chairman & Chief Executive Officer
  • Geoff Race, President
  • Joseph Reilly, Chief Operating Officer & Senior Vice President
  • Fred Ahlholm, Chief Financial Officer & Senior VP-Finance
  • Michael Davidson, Chief Medical Officer

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $0.83.

How much money does Minerva Neurosciences make?

Minerva Neurosciences has a market capitalization of $35.67 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $1.94 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Minerva Neurosciences have?

Minerva Neurosciences employs 11 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Where are Minerva Neurosciences' headquarters?

Minerva Neurosciences is headquartered at 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.